Patents by Inventor Sanjeev Gangwar

Sanjeev Gangwar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD10-activated prodrug compounds
    Patent number: 7771962
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing the prodrug are also disclosed.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: August 10, 2010
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF
    Publication number: 20100145036
    Abstract: The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Application
    Filed: December 28, 2007
    Publication date: June 10, 2010
    Applicant: Medarex, Inc.
    Inventors: Bilal Sufi, Vincent Guerlavais, Liang Chen, Sanjeev Gangwar, Qian Zhang, David B. Passmore
  • Cytotoxic compounds and conjugates with cleavable substrates
    Patent number: 7714016
    Abstract: The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them.
    Type: Grant
    Filed: April 6, 2006
    Date of Patent: May 11, 2010
    Assignee: Medarex, Inc.
    Inventors: Sanjeev Gangwar, Bilal Sufi
  • CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF
    Publication number: 20100113476
    Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Application
    Filed: February 20, 2008
    Publication date: May 6, 2010
    Inventors: Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Nils Lonberg, Qian Zhang
  • CHEMICAL LINKERS AND CONJUGATES THEREOF
    Publication number: 20100092496
    Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Application
    Filed: November 2, 2009
    Publication date: April 15, 2010
    Applicant: Medarex, Inc.
    Inventors: Sharon E. Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Killian Horgan, Zhi-Hong Li, Bilal Sufi
  • Prodrug compounds with isoleucine
    Patent number: 7696313
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: April 13, 2010
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • Chemical linkers and conjugates thereof
    Patent number: 7691962
    Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: April 6, 2010
    Assignee: Medarex, Inc.
    Inventors: Sharon E. Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Killian Horgan, Zhi-Hong Li, Bilal Sufi
  • PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR
    Publication number: 20090209734
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Application
    Filed: March 4, 2009
    Publication date: August 20, 2009
    Applicant: Medarex, Inc.
    Inventors: Howard P. Ng, Danny P.C. McGee, Guoxian Wu, Jimmie Moore, Zhihong Li, Sanjeev Gangwar, Oliver L. Saunders, Irina Astafieva
  • FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE
    Publication number: 20090162372
    Abstract: The present invention provides anti-ED-B antibodies, antibody fragments, and antibody mimetics and such antibodies conjugated to a partner molecule, wherein the antibody or the antibody-partner molecule conjugate provides a therapeutic effect regardless of whether the ED-B-antibody or ED-B-conjugate complex is internalized within a targeted cell.
    Type: Application
    Filed: November 14, 2008
    Publication date: June 25, 2009
    Applicant: Medarex, Inc.
    Inventors: David J. KING, Jonathan A. Terrett, Sanjeev Gangwar, Josephine M. Cardarelli, Chetana Rao-Naik, Chin Pan
  • CD10-activated prodrug compounds
    Publication number: 20090136980
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing the prodrug are also disclosed.
    Type: Application
    Filed: November 20, 2007
    Publication date: May 28, 2009
    Applicant: MEDAREX, INC.
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • Enzyme-cleavable prodrug compounds
    Publication number: 20090110753
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.
    Type: Application
    Filed: August 14, 2008
    Publication date: April 30, 2009
    Applicant: MEDAREX, INC.
    Inventors: Vincent Dubois, Anne Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • Cytotoxic compounds and conjugates
    Patent number: 7517903
    Abstract: The present disclosure provides drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-cleavable substrate conjugates, and to methods of treatment using them.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: April 14, 2009
    Assignee: Medarex, Inc.
    Inventors: Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Zhi-Hong Li, Bilal Sufi
  • Peptidyl prodrugs and linkers and stabilizers useful therefor
    Patent number: 7507420
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: March 24, 2009
    Assignee: Medarex, Inc.
    Inventors: Howard P. Ng, Danny P. C. McGee, Guoxian Wu, Jimmie Moore, Zhi-Hong Li, Sanjeev Gangwar, Oliver L. Saunders, Irina Astafieva
  • Cytotoxic Compounds and Conjugates
    Publication number: 20080293800
    Abstract: The present disclosure provides cytoxic compounds useful as drugs or prodrugs and to drug-cleavable substrate conjugates where the drug and cleavable substrate are optionally linked through a self-immolative linker.
    Type: Application
    Filed: November 9, 2006
    Publication date: November 27, 2008
    Applicant: MEDAREX, INC.
    Inventors: Sanjeev Gangwar, Bilal Sufi
  • Methods and Compounds For Preparing Cc-1065 Analogs
    Publication number: 20080281102
    Abstract: A method of forming a CBI CC-1065 analog utilizes NH2 as a starting material, where R3 is H or alkyl and R6 is H, substituted or unsubstituted lower alkyl, cyano, or alkoxy. Intermediates (I) are used and are claimed.
    Type: Application
    Filed: October 18, 2006
    Publication date: November 13, 2008
    Applicant: MEDAREX, INC.
    Inventors: Sanjeev Gangwar, Qian Zhang
  • Antibody-Drug Conjugates and Methods of Use
    Publication number: 20080279868
    Abstract: The present disclosure provides antibody-drug conjugates that are potent cytotoxins, wherein the drug is linked to the antibody through a linker. The disclosure is also directed to compositions containing the antibody-drug conjugates, and to methods of treatment using them.
    Type: Application
    Filed: September 26, 2006
    Publication date: November 13, 2008
    Applicant: Medarex, Inc.
    Inventors: Sharon Elaine Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Kilian Horgan, Bilal Sufi, Haichun Huang, David John King, Chin Pan, Josephine M. Cardarelli
  • Prodrug compounds with isoleucine
    Publication number: 20080255248
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: January 16, 2008
    Publication date: October 16, 2008
    Applicant: MEDAREX, INC.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • Enzyme-cleavable prodrug compounds
    Patent number: 7425541
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: September 16, 2008
    Assignee: Medarex, Inc.
    Inventors: Vincent Dubois, Ann Marie Fernandez, Sanjeev Gangwar, Evan Lewis, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey Yarranton
  • Prodrug compounds with isoleucine
    Patent number: 7329507
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: February 12, 2008
    Assignee: Medarex, Inc.
    Inventors: Lesley B. Pickford, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Geoffrey T. Yarranton
  • Peptidyl prodrugs and linkers and stabilizers useful therefor
    Patent number: RE41252
    Abstract: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: April 20, 2010
    Assignee: Medarex, Inc.
    Inventors: Howard P. Ng, Danny P. C. McGee, Guoxian Wu, Jimmie Moore, Zhi-Hong Li, Sanjeev Gangwar, Oliver L. Saunder, Irina Astafieva, Valeri Martichonok